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Joint estimation of CD4R cell progression and survival
in untreated individuals with HIV-1 infection
Tara D. Mangal, on behalf of the UNAIDS Working Group on CD4
Progression and Mortality Amongst HIV Seroconverters including the
CASCADE Collaboration in EuroCoord
Objective: We compiled the largest dataset of seroconverter cohorts to date from 25
countries across Africa, North America, Europe, and Southeast/East (SE/E) Asia to
simultaneously estimate transition rates between CD4þ cell stages and death, in
antiretroviral therapy (ART)-naive HIV-1-infected individuals.
Design: A hidden Markov model incorporating a misclassification matrix was used to
represent natural short-term fluctuations and measurement errors in CD4þ cell counts.
Covariates were included to estimate the transition rates and survival probabilities for
each subgroup.
Results: The median follow-up time for 16373 eligible individuals was 4.1 years
(interquartile range 1.7–7.1), and the mean age at seroconversion was 31.1 years
(SD 8.8). A total of 14 525 individuals had recorded CD4þ cell counts pre-ART, 1885
died, and 6947 initiated ART. Median (interquartile range) survival for men aged 20
years at seroconversion was 13.0 (12.4–13.4), 11.6 (10.9–12.3), and 8.3 years (7.9–
8.9) in Europe/North America, Africa, and SE/E Asia, respectively. Mortality rates
increase with age (hazard ratio 2.22, 95% confidence interval 1.84–2.67 for >45
years compared with <25 years) and vary by region (hazard ratio 2.68, 1.75–4.12 for
Africa and 1.88, 1.50–2.35 for Asia compared with Europe/North America). CD4þ cell
decline was significantly faster in Asian cohorts compared with Europe/North America
(hazard ratio 1.45, 1.36–1.54).
Conclusion: Mortality and CD4þ cell progression rates exhibited regional and age-
specific differences, with decreased survival in African and SE/E Asian cohorts com-
pared with Europe/North America and in older age groups. This extensive dataset
reveals heterogeneities between regions and ages, which should be incorporated into
future HIV models. Copyright  2017 The Author(s). Published by Wolters Kluwer Health, Inc.
AIDS 2017, 31:1073–1082
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Introduction
A good characterization of HIV natural history is essential
to track epidemic trends, estimate incidence, determine
treatment needs, and estimate the impact of interventions
to reduce AIDS mortality. Current estimates of CD4þ
cell progression and survival have been derived from
analyses employing different approaches, combined to
approximate a Markov transition model [1–3]. CD4þ cell
progression estimates tend to come from linear mixed
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effects models [4–7], and mortality estimates are generally
derived from survival analyses [8,9]. To consistently use
both sources of data requires a Markov model for
estimation, which simultaneously describes the process of
CD4þ cell decline and survival.
There is evidence for increased disease progression
by age across all exposure categories, but suggestions
of differences between the sexes are inconclusive
[4,10–14]. Faster progression in persons from Africa
compared with Europe, after adjusting for age, has been
found in some studies, whereas others have found no
significant differences [6,10,15]. In addition, some
studies report faster CD4þ cell decline and shorter
survival in Asian cohorts compared with Europe or
Africa. For example, Todd et al. [8] report median gross
survival times of 11.1 and 11.6 years in East and South
Africa, respectively, and 7.5 years for Thai cohorts.
Similarly, a comparison between the Concerted Action
on Seroconversion to AIDS and Death in Europe
(CASCADE) collaboration and the Beijing PRIMO
cohort found significantly faster CD4þ cell decline in
the Beijing cohort [16].
No previous study has directly compared progression and
survival times in multiple regions using empirical data
from individuals with well estimated seroconversion dates
(i.e. the date at which an infected individual begins to
develop antibodies to the HIV virus). CD4þ cell counts
are subject to measurement error and natural short
timescale variability, producing a noisy observable marker
of progression. For that reason, we use a hidden Markov
model that allows joint estimation of CD4þ cell
progression and survival without prior knowledge of
time of infection along with estimation of the impact of
time-dependent covariates [17–19]. Informative censor-
ing such as initiation of ART, provided selectively to those
with severe disease, can be accommodated by introducing
a competing hazards element.
Here we summarize data from seroconverter cohorts
from 25 countries across four geographic regions:
Africa, North America, Europe, and Southeast/East
(SE/E) Asia. We use this extensive dataset to describe
the natural history of HIV infection using CD4þ cell
counts as a marker, estimating differences among age
groups, sex, and regions. We simultaneously estimate
transition rates between CD4þ cell stages and time from
seroconversion to death and discuss the likely impact of
demographic characteristics on the progression of
HIV infection.
Methods
Study population
We identified seroconverter cohorts from a systematic
review of published articles and conference abstracts,
inviting those with laboratory evidence of recent
seroconversion or reported intervals between negative
and positive HIV tests results along with CD4þ cell
counts to participate. The CASCADE collaboration
comprises the majority of seroconverters in our dataset,
with 29 separate cohorts in 13 countries. An additional 24
studies were included, resulting in a pooled dataset
comprising 30 164 individuals monitored during 1979–
2014 across 25 countries (Table S1, http://links.lww.
com/QAD/B52). Data were grouped by region
(Europe/North America, Africa, and SE/E Asia) for
analysis to assess geographical variations in natural history.
Many of the studies contained detailed immunological,
virological, and clinical data along with individual
characteristics. A limited number contained no immuno-
logical information but were included as they furnished
information on survival prior to the availability of ART.
For 98.5% of individuals, the date of infection
(seroconversion) was estimated as the midpoint between
the last seronegative and first seropositive results.
Seroconversion dates for the remaining individuals were
estimated using laboratory evidence of seroconversion,
seroconversion illness, or using unspecified methods.
Individuals between 15 and 65 years of age at
seroconversion with seroconversion intervals of less than
1 year were included in the main analysis. We repeated the
analysis using seroconversion intervals of up to 2 years to
examine the potential effect of this criterion on initial
state probability estimates.
The hidden Markov model
The Markov model represents CD4þ cell decline
following seroconversion due to HIV-1 infection as
transitions through a series of seven CD4þ cell count
categories and from each CD4þ cell stage to death
(Fig. 1). Transition rates to ART, included as an absorbing
state, were estimated as ancillary parameters to reflect the
data [20].
The transition rates (lrs) describe the instantaneous
rate of movement between states r and s and values of
the transition matrix (Q) on the diagonal (lrr) were
fixed to minus the sum of the entries in each row
(Fig. S1, http://links.lww.com/QAD/B52). We allowed
only forward transitions between adjacent CD4þ
cell-based states, consistent with the underlying biology
[17–19]. A misclassification matrix with entries r,s
describes the probability of observing a CD4þ cell
count in state r conditionally on the true state s. Thus,
any apparent backwards transitions between states with
lower CD4þ cell count to states with higher CD4þ cell
count were assumed to be explained by short-term
reversible fluctuations in combination with measure-
ment error. The two absorbing states corresponding
with ARTand death were assumed to be recorded error-
free.
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Individuals can enter into any of the transient states at
seroconversion, defined by CD4þ cell counts of more
than 500, 351–500, 251–350, 201–250, 101–200, 51–
100, and 50 CD4þ cells/ml or less. Short time-scale
variability in the measured CD4þ cell counts was
stabilized by log-transformation.
Individual-level covariates age (time-dependent), sex,
and region were included as explanatory variables on the
transition rates. The transition rate (l) for individual i at
observation time j is conditional on a vector of covariate
values z with a vector of coefficients (b) estimated using
multinomial logistic regression:
lrs zi j
  ¼ lrsð0Þexp brsT zi j
 
where r and s represent a pair of states, for each nonzero
entry of the transition matrix (Q) [21].
We included a separate absorbing state for transitions to
ART to reduce bias caused by informative censoring, that
is, individuals with lower CD4þ cell counts are more
likely to be censored due to ART initiation than
individuals with higher counts. We use the recorded date
of ART initiation as the exact transition time to the ART
absorbing state and consider only those individuals
receiving HAART. These parameters are jointly esti-
mated during the model fitting but discarded for the
survival time calculations. That is, all survival estimates are
calculated conditionally on not receiving ART.
The transition rates were used to calculate the median
survival time from seroconversion to death, using the
cumulative transition probability distributions of the time
from all CD4þcell-based states to death, weighted by the
initial state probabilities, and accounting for the changing
age of the person.
Model fitting and parameter estimation
The Markov model was fit using the msm package in R
(R Foundation for Statistical Computing, Vienna,
Austria. URL http://www.R-project.org/) [21]. We
fitted the model directly to the data, without smoothing,
incorporating the measurement error structure directly
into the likelihood function. To ensure convergence to
the true maximum likelihood, we used Latin hypercube
sampling to generate 10 000 sets of initial values from a
plausible range and selected the 10 parameter combi-
nations with the greatest log-likelihood [22].
We then started optimization algorithms using these 10
parameter sets to find the optimum parameter estimates.
Single-covariate models were developed incorporating
current age, sex, and region variables on transition
intensities and initial state probabilities, and compared
with a baseline model containing no covariates. Con-
strained models that estimated one covariate effect for each
transition type (i.e. for transitions among CD4þ cell states,
to ART, and to death) were compared with a saturated
model allowing covariate effects to be estimated separately
for every transition. The likelihood ratio test was used to
select covariates that improved the model fit and we
selected the most parsimonious model representing the
associations between each covariate and thedisease process.
Confidence limits were obtained by nonparametric
bootstrap resampling using 5000 resampled sets.
To examine the effect of clinical AIDS diagnosis as a
potential bias in the survival estimates, under the
assumption that at this point individuals may be receiving
additional medical care prolonging their lives, a sensitivity
analysis was performed that excluded all observations
recorded after an AIDS diagnosis.
Ethical approval
Separate ethical approval was not required for this study as
this was a secondary analysis of fully anonymized existing
datasets. Ethical approval was obtained by each individual
study and can be accessed from the original publications.
Results
Study characteristics
Of the 30 164 individuals in the 25 included studies,
16 373 were eligible for inclusion in the analysis (Fig. 2);
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Death
ART
λ19 λ29 λ39 λ49 λ59 λ69 λ79
λ18 λ28 λ38 λ48 λ58 λ68 λ78
λ12 λ23 λ34 λ45 λ56 λ67
Fig. 1. The staged Markov model of HIV disease progression.
14 525 had recorded CD4þ cell counts, 6947 initiated
ART, and 1885 deaths were observed (Table 1). The
mean age at seroconversion was 31.1 years (SD 8.8), 77%
were men, and a median of 6 [interquartile range (IQR)
3–13] CD4þ cell measurements had been recorded over
4.1 years (IQR 1.7–7.1).
Model selection
Each covariate (age, sex, and region) significantly
improved the model fit (likelihood ratio test, all
P< 0.001) compared with the baseline model and so
were retained in the final model. There was no significant
improvement when allowing covariate effects to be
estimated independently for each transition rate com-
pared with constraining the covariate effects (P> 0.05),
and so we opted for the more parsimonious model.
Initial state probabilities
As individuals age, their estimated CD4þ cell count at
seroconversion decreases (Fig. 3). The probability of
being in the highest state (CD4þ cell count >500 cells/
ml) after seroconversion falls from 0.57 for ages 15–24
years to 0.41 for those aged at least 45 years for European
and North American men and from 0.54 to 0.38 for
African men. CD4þ cell counts at seroconversion were
lower among Asian cohorts; only 0.41 of men aged 15–
24 years in the SE/E Asian cohorts seroconvert into the
highest CD4þ cell state. Including individuals with
longer seroconversion intervals, that is, up to 2 years
between the last negative and the first positive test
produced qualitatively similar findings (Table S2, http://
links.lww.com/QAD/B52).
Progression between CD4R cell states and
mortality rates
The progression rates between CD4þ cell states were not
strongly influenced by age (Table 2); however, older
individuals experience higher mortality rates [hazard ratio
2.22, 95% confidence interval (CI) 1.84–2.67 for 45-
year-olds compared with <25 years]. Estimates of the
transition rates for 15–24-year-olds, by sex and region,
are presented in Tables 3 and 4. Women were estimated to
have slightly slower progression rates between CD4þ cell
states than men (hazard ratio 0.92, 95% CI 0.86–0.99),
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Fig. 2. Geographic distribution of 16373 HIV-1-infected individuals enrolled throughout 1979–2014, in 25 countriesM.
Missing values: 699 cases categorized as ‘sub-Saharan Africa’ and six cases in ‘Europe’.
Table 1. Selected characteristics of 16373 HIV-infected individuals, by region.
Eligible
seroconverters
Mean age at
seroconversion
[years (SD)]
Proportion
men
Study
period
Median follow-up
time [years (2.5th and
97.5th percentiles)]
Median
CD4þ cell
counts (range)
Number
of deaths
North America 1492 29.06 (7.99) 0.95 1984–2012 3.41 (0.06–12.42) 3 (1–75) 56
Europe 10950 31.75 (8.99) 0.79 1979–2012 4.36 (0.61–15.53) 7 (1–199) 1199
Africa 3341 30.42 (8.10) 0.59 1987–2014 4.45 (0.37–11.41) 7 (1–41) 545
SE/E Asia 590 27.34 (7.89) 0.96 1989–2013 3.37 (0.12–7.39) 6 (1–17) 85
SE/E Asia, Southeast/East Asia.
but there were no significant differences in overall
mortality rates between men and women (hazard ratio
1.04, 95% CI 1.00–1.08). Mortality rates were higher in
cohorts from Africa and SE/E Asia (hazard ratio 2.68,
95% CI 1.75–4.12 and hazard ratio 1.88, 95% CI 1.50–
2.35, respectively) compared with Europe and North
America, but CD4þ cell decline was faster only for Asian
cohorts (hazard ratio 1.45, 95% CI 1.36–1.54).
Overall survival times
Survival in SE/E Asia was substantially shorter than in
other regions, with median survival estimates of 8.3 years
(IQR 7.9–8.9) for men aged 20 years compared with
13.0 and 11.6 years in Europe and Africa, respectively
(Table 5). Removing observations occurring after a
clinical AIDS diagnosis results in qualitatively similar
findings, although survival estimates are shorter by an
average of 10 months (Table S3, http://links.lww.com/
QAD/B52).
Model assessment
There is substantial misclassification between observed
and underlying states in the intermediate stages of disease
as expected, given the narrow ranges of these states and
the high variability in individual CD4þ cell dynamics
(Table S4, http://links.lww.com/QAD/B52). We see the
greatest agreement between observed and underlying
states in those with the highest CD4þ cell counts (0.935,
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Fig. 3. Initial state probabilities at seroconversion for HIV-1-infected individuals stratified by region and age for 12567 men
(a–c) and 3806 women (d–f). States 1–4 represent CD4þ cell counts of more than 500, 351–500, 251–350, and 201–250 cells/
ml, respectively.
Table 2. Estimated hazard ratios (95% confidence interval) for covariates (current age, sex, and region) on transition rates of 16373 individuals
using a proportional intensities model.
Progression ART Mortality
Age-group (years)
15–24 (reference) 1.0 1.0
25–34 1.01 (0.94–1.10) 1.25 (1.13–1.40)
35–44 0.94 (0.87–1.03) 1.55 (1.35–1.78)
>45 0.93 (0.86–1.01) 2.22 (1.84–2.67)
Sex
Male (reference) 1.0 1.0
Female 0.92 (0.86–0.99) 1.04 (1.00–1.08)
Region
Europe/North America (reference) 1.0 1.0 1.0
Africa 0.97 (0.77–1.21) 0.21 (0.16–0.28) 2.68 (1.75–4.12)
SE/E Asia 1.45 (1.36–1.54) 0.50 (0.33–0.76) 1.88 (1.50–2.35)
ART, antiretroviral therapy; SE/E Asia, Southeast/East Asia.
95% CI 0.896–0.976 for CD4þ cell count>500 cells/ml)
and the lowest counts (0.956, 95% CI 0.882–1.0 for
CD4þ cell count 50 cells/ml). Using the fitted
transition probability matrix and the misclassification
matrix to forecast expected prevalences shows a similar
pattern (Fig. S2, http://links.lww.com/QAD/B52).
Discussion
We used the largest database to date of seroconverters
infected with HIV-1 to jointly estimate the rates of
immune function decline and survival across four
continents, thus providing the most comprehensive
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Table 5. Median survival estimates in years (interquartile range) from 5000 bootstrapped samples by region for 16373 HIV-1-infected
individuals in 25 countries during 1979–2014.
Europe/North America Africa SE/E Asia
Age at
seroconversion
(years) Men Women Men Women Men Women
20 13.0 (12.4–13.4) 3072 13.5 (12.9–14.2) 1444 11.6 (10.9–12.3) 402 10.7 (10.0–12.2) 535 8.3 (7.9–8.9) 302 8.2 (7.8–9.0) 18
30 12.1 (11.6–12.6) 5753 12.5 (11.9–13.4) 1650 10.8 (9.9–11.5) 979 9.7 (9.0–11.5) 618 7.7 (7.3–8.4) 169 7.6 (7.1–8.4) 4
40 10.7 (10.1–11.3) 2630 11.2 (11.1–11.5) 497 9.0 (8.2–10.2) 430 8.1 (7.4–10.2) 174 6.7 (6.3–7.5) 67 6.6 (6.1–7.5) 2
Number of individuals in each category is in italics. SE/E Asia, Southeast/East Asia.
Table 3. Estimated annual transition rates (95% confidence interval) of the CD4R cell-based Markov model of HIV natural history by region for
3072 men aged 15–24 years.
Europe/North America Africa SE/E Asia
Progression rates
l12 0.205 (0.141–0.299) 0.198 (0.127–0.309) 0.297 (0.203–0.436)
l23 0.341 (0.180–0.644) 0.329 (0.178–0.610) 0.493 (0.261–0.932)
l34 0.348 (0.143–0.848) 0.336 (0.123–0.917) 0.504 (0.205–1.242)
l45 0.527 (0.188–1.478) 0.509 (0.165–1.574) 0.763 (0.266–2.187)
l56 0.593 (0.229–1.530) 0.573 (0.185–1.771) 0.858 (0.321–2.295)
l67 0.897 (0.178–4.529) 0.867 (0.169–4.443) 1.300 (0.255–6.616)
Mortality rates
l19 0.001 (0–0.004) 0.003 (0.001–0.014) 0.002 (0.001–0.009)
l29 0.003 (0.001–0.012) 0.009 (0.002–0.039) 0.006 (0.002–0.025)
l39 0.003 (0.001–0.006) 0.007 (0.003–0.018) 0.005 (0.002–0.012)
l49 0.005 (0.001–0.023) 0.013 (0.002–0.067) 0.009 (0.002–0.045)
l59 0.008 (0.003–0.024) 0.022 (0.006–0.073) 0.015 (0.005–0.048)
l69 0.014 (0.002–0.113) 0.037 (0.004–0.349) 0.026 (0.003–0.237)
l79 0.315 (0.217–0.459) 0.845 (0.418–1.709) 0.592 (0.359–0.976)
Refer to Fig. 1 for schematic representation of transition rates. SE/E Asia, Southeast/East Asia.
Table 4. Estimated annual transition rates (95% confidence interval) of the CD4R cell-based Markov model of HIV natural history by region for
1444 women aged 15–24 years.
Europe/North America Africa SE/E Asia
Progression rates
l12 0.190 (0.131–0.276) 0.184 (0.121–0.280) 0.275 (0.189–0.400)
l23 0.315 (0.164–0.606) 0.305 (0.164–0.567) 0.457 (0.239–0.876)
l34 0.322 (0.136–0.763) 0.311 (0.118–0.820) 0.466 (0.195–1.114)
l45 0.488 (0.175–1.362) 0.471 (0.154–1.438) 0.707 (0.248–2.014)
l56 0.548 (0.217–1.385) 0.530 (0.176–1.596) 0.794 (0.304–2.075)
l67 0.830 (0.162–4.257) 0.802 (0.155–4.152) 1.202 (0.233–6.21)
Mortality rates
l19 0.001 (0–0.004) 0.003 (0.001–0.013) 0.002 (0.001–0.008)
l29 0.004 (0.001–0.014) 0.009 (0.002–0.039) 0.007 (0.002–0.027)
l39 0.003 (0.001–0.006) 0.008 (0.003–0.020) 0.005 (0.002–0.011)
l49 0.005 (0.001–0.024) 0.013 (0.002–0.069) 0.009 (0.002–0.046)
l59 0.008 (0.003–0.024) 0.022 (0.006–0.075) 0.016 (0.005–0.051)
l69 0.014 (0.002–0.113) 0.039 (0.004–0.364) 0.027 (0.003–0.243)
l79 0.328 (0.221–0.486) 0.878 (0.424–1.817) 0.615 (0.366–1.033)
Refer to Fig. 1 for schematic representation of transition rates. SE/E Asia, Southeast/East Asia.
estimates of the natural history of HIV. CD4þ cell counts
in HIV-negative populations are highly variable, decreas-
ing with age and lower in men compared with women
[23–26]. We found that individuals infected at an older
age were more likely to have lower CD4þ cell counts at
seroconversion and higher mortality rates similar to other
published analyses [8,9,27,28]. Progression rates did not
vary by current age, although some studies have found
differences by age at seroconversion [4,29,30]. Interest-
ingly, the strongest predictor of progression and mortality
is the region from which the cohort originated. Various
studies have found slower progression in African
compared with European cohorts, and some have also
documented lower CD4þ cell counts at seroconversion
with no increase in mortality [6,23,31,32]. However,
these differences could be driven by environmental
factors and differential access to healthcare rather than
ethnicity as Africans living in London experienced similar
progression rates to non-Africans [10,33]. As we do not
differentiate between different ethnicities but stratify by
geographic region, and aim to remove the effects of access
to treatment, it is not surprising that we do not detect
significantly slower progression in the African cohorts
compared with the European and North American
cohorts. Cohorts from SE/E Asia experience faster
CD4þ cell decline and higher mortality rates, and this, in
combination with lower CD4þ cell counts at the time of
seroconversion, leads to significantly shorter survival
times compared with the other regions. A study across 17
clinical sites in Asia showed the total lymphocyte count
and CD4þ cell count in untreated HIV-infected persons
to be lower compared with a clinical study conducted in
France [34]. The authors cite several potential expla-
nations for the finding including variations in immune
function or genetic factors. Differences in virus subtype
(subtype CRF01_AE is the predominant form in
Southeast Asia) could also influence progression rates
[35]. In addition, lower CD4þ cell counts at seroconver-
sion [16], faster CD4þ cell decline [16,36], and higher
mortality rates in Asian populations compared with
Europeans have been observed. Other studies have also
noted lower CD4þ cell counts in HIV-negative
individuals in Asian cohorts compared with Europeans.
After controlling for differences in transition rates by
age and region, we find no clear differences in mortality
rates between men and women and only marginal
differences in progression rates in line with previous
studies [7,27].
Our survival estimates agree well with earlier studies,
although our estimates in older age groups tend to be
slightly longer. Estimates of median survival times in
European cohorts in the CASCADE collaboration for
ages 15–24, 25–34, and 35–45 years were 12.5 (95% CI
12.1–12.9), 10.9 (10.9–11.3) and 9.1 years (8.7–9.5),
respectively [9]. For the same age groups, we predict
mean survival times of 12.3–13.2, 10.9–12.3, and 10.7–
10.9 years. Published estimates for mean survival in men
aged 25–29 years in South Africa are 11.6 years (95% CI
9.8–13.7), East Africa 11.1 years (95% CI 8.7–14.2), and
Thailand 7.5 years (95% CI 5.4–10.4) [8]. Again, we find
similar values of 10.3–10.4 years for African men and
7.2–7.7 years in men for Thailand, Singapore, and China.
Although we generalize our findings to Europe/North
America and Africa, the European data originate from
Western Europe, and the African data are clustered in East
and South Africa. SE/E Asia region includes data from
Thailand, Singapore, and China. The expected survival
times estimated by the Markov model are extrapolated
under the assumption that the transition probabilities are
constant and will remain constant in the future, meaning
that the transitions to ART, estimated as a means of
reducing bias, are averaged across the study period.
However, as expected, the rates of initiating ART are
lower in Africa and Asia compared with Europe,
consistent with the later availability in these regions
along with lower uptake. Applying a Kaplan–Meier
analysis that ignores this bias results in implausibly long
survival times (Fig. S3, http://links.lww.com/QAD/
B52).
One assumption of the staged Markov model is that the
observations occur at random intervals (i.e. not following
acute events or due to patient self-selection), which could
lead to sampling bias. There is also a bias towards longer
survivors present in all studies of this type. Individuals are
both right-censored (removed from the study due to
various circumstances) and left-censored (they enter the
study at some unknown stage of the disease). Although
some evidence suggests longer survival times in later
stages of the epidemic, this is likely to be confounded with
access to ARTor improved healthcare [37]. Data on mode
of acquisition are available for 70% of individuals in this
database, and the majority of our data are from MSM
(53% of known risk groups) followed by men who have
sex with women (28%). We do not distinguish between
risk groups here, as additional stratification in our model
would result in very low numbers in each subgroup,
preventing us from obtaining reliable estimates. There is
mounting evidence suggesting that progression rates can
be influenced by host characteristics such as human
leukocyte antigen, virus subtype, and set-point viral load
[38–43]. A natural next step would be to include this
information in our model and investigate whether the
regional differences found here can be explained by
variations in viral dynamics [44–46].
Our results are based on the largest ever compiled dataset
of seroconverters and give important insights into the
influence of demographic factors on CD4þ cell
progression and survival, highlighting a need for HIV
care guidelines to be tailored to specific subgroups. The
faster progression and shorter survival times in the cohorts
from SE/E Asia are of particular importance, and further
investigation is necessary to understand the biological
mechanisms of these differences.
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